Andrew Nelsen is an emerging leader at United Therapeutics, a major biotechnology company that is widely known for its focus on lifesaving therapies and organ manufacturing technologies. In recent years, Nelsen has become increasingly visible within the organization as a key voice for clinical innovation, medical engagement, and global medical affairs. He represents a new generation of professionals bringing deep pharmaceutical knowledge, strategic scientific communication, and practical experience in advancing treatments for complex diseases such as pulmonary arterial hypertension and interstitial lung disease. United Therapeutics itself is a public benefit corporation dedicated to improving patient outcomes through new medicines and technologies that expand organ availability and address unmet medical needs.
Background and Role at United Therapeutics
Andrew Nelsen serves as Associate Vice President of Medical Engagement & Capabilities at , where he plays a central role in shaping the company’s clinical discourse and research outreach. His responsibilities include coordinating medical communication strategies, engaging with clinicians and researchers, and presenting United Therapeutics’ latest scientific findings at major healthcare conferences.
Nelsen’s professional background is rooted in pharmacy and medical affairs, and he typically uses the designation PharmD, indicating his training in pharmacy. This training equips him with a strong foundation in drug therapy, clinical pharmacology, and patient careskills that are valuable in complex therapeutic areas like pulmonary hypertension. His medical expertise allows him to work closely with research teams, physicians, and scientific institutions to ensure that clinical data is accurately interpreted and clearly communicated to the broader medical community.
United Therapeutics Mission and Impact
United Therapeutics is a biotechnology company dedicated to creating innovative treatment options for rare diseases, especially those affecting the heart and lungs. Founded in 1996, the company has become known for its novel pharmaceutical therapies and advanced transplant technologies. Its mission is to improve patient lives through breakthrough science while balancing shareholder value and public benefit.
As a public benefit corporation, United Therapeutics has a strong emphasis on contributing to healthcare improvements rather than focusing solely on profits. The company’s work spans pulmonary hypertension treatments, xenotransplantation research, and organ manufacturingfields that require collaboration between science, medicine, and industry partners. Within this environment, professionals like Andrew Nelsen help bridge the gap between clinical research and realworld medical application.
Leadership in Global Medical Affairs
Nelsen’s role in global medical affairs places him at the intersection of scientific research, clinical strategy, and communication. One of his key duties is to ensure that United Therapeutics’ medical insights are shared effectively with healthcare professionals, researchers, and scientific audiences around the world.
For example, he has delivered presentations on behalf of United Therapeutics at major medical conferences such as the American Thoracic Society International Conference, where he discussed interim clinical data from studies evaluating new therapies for pulmonary arterial hypertension. These forums allow Nelsen to highlight important developments in the field, explain complex clinical results, and engage in dialogue with peers about emerging treatment paradigms.
Presentations and Scientific Communication
At such conferences, Andrew Nelsen often speaks about the latest clinical research findings and ongoing trials involving United Therapeutics’ products. His presentations are tailored to a professional audience, including physicians, clinical researchers, and policy experts, and they play a role in shaping scientific understanding of innovative therapies.
For instance, in 2025 he presented interim efficacy data from the ADVANCE EXTENSION study related to ralinepag, a compound being evaluated for pulmonary arterial hypertension. He also participated in discussions on how these therapies could influence the broader landscape of treatment options in these diseases.
Contributions to Research and Publications
In addition to speaking engagements, Andrew Nelsen contributes to research topics and scientific publications. Academic publications often involve complex data analysis and methodological contributions from professionals like Nelsen, who collaborate with clinical scientists on studies that analyze treatment patterns, outcomes, and advancements in care.
Such contributions help extend the scientific credibility not only of United Therapeutics’ medicines but also of the broader field of pulmonary vascular disease research. By participating in research efforts, Nelsen supports the company’s objective of improving patient care through welldocumented evidence and academic collaboration.
Skills and Expertise
Andrew Nelsen’s expertise lies in medical engagement, clinical communication, and strategic research positioning. His pharmacy training enables him to interpret complex clinical data and translate it into meaningful presentations for clinicians and researchers. Additionally, he collaborates across departments to align scientific strategy with United Therapeutics’ overarching mission to develop novel therapies for rare and lifethreatening conditions.
Nelsen also works closely with global research teams to understand evolving disease landscapes, regulatory environments, and clinical endpoints. This integrative approach helps United Therapeutics advance treatments in a way that meets both scientific standards and patient needs.
The Broader Importance of United Therapeutics’ Work
The research and development work at United Therapeutics has a meaningful impact on patients affected by pulmonary arterial hypertension and other serious conditions. By focusing on therapies that address unmet needs, the company contributes to medical progress and offers hope to individuals who may otherwise have limited treatment options.
Beyond drug development, United Therapeutics also explores advanced technologies aimed at expanding the availability of transplantable organs. Initiatives such as xenotransplantation research and organ preservation technologies could revolutionize organ transplantation in the futurea longterm goal that aligns with the company’s commitment to patient benefit.
How Nelsen’s Role Aligns With Company Goals
Andrew Nelsen’s work in medical affairs supports the strategic goals of United Therapeutics in several ways. First, his communication efforts help raise awareness about new clinical data and emerging therapies among medical professionals. This awareness can influence treatment decisions and encourage further research collaborations.
Second, his engagement at scientific meetings strengthens the company’s reputation within the healthcare community. As peers and industry leaders hear from United Therapeutics representatives like Nelsen, the company reinforces its position as a trusted source of data and insight in rare disease treatment.
Future Perspectives
Looking ahead, professionals like Andrew Nelsen will likely continue to play a key role in how pharmaceutical companies communicate scientific advances and collaborate with global medical communities. As United Therapeutics expands its research portfolio and explores new therapeutic areas, medical engagement leaders will be essential in guiding conversations about clinical efficacy, patient impact, and innovation.
By continuing to build bridges between research, clinical practice, and patient outcomes, Nelsen and his colleagues help ensure that complex scientific progress translates into real benefits for patients around the world.
Andrew Nelsen represents a vital part of the scientific leadership at United Therapeutics. Through his role in medical engagement, research communication, and clinical presentations, he helps drive the company’s mission to deliver innovative therapies and improve patient care. His background in pharmacy and his active participation in scientific discourse highlight the importance of effective communication and collaboration in advancing medical science and enhancing global health outcomes.